Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Regeneron Pharmaceuticals
Children's Oncology Group
Sunnybrook Health Sciences Centre
Roswell Park Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)